Positive 52-Week Maintenance Data Observed with Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (SEASIDE CHINA)
Revolutionizing Atopic Dermatitis (RAD 2024) Conference, June 8-10, 2024

Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002)
American Thoracic Society 2024 (ATS 2024), May 17-22, 2024

Efficacy and safety of icanbelimod(CBP-307) in adults with moderate-to-severe ulcerative colitis: A phase 2, randomized, double-blind, placebo-controlled trial.
Presented at the Advances in Inflammatory Bowel Diseases, December 14-16, 2023

Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases.
Zhang, L., Ding, Y., Wang, Q. et al. Sci Rep 13, 12411 (2023)

WCD 2023 Primary Poster_19June2023
Presented at the World Congress of Dermatology, July 3-8, 2023

WCD 2023 EASI and Safety Poster_19June2023
Presented at the World Congress of Dermatology, July 3-8, 2023

WCD 2023 Investigator Reported Outcomes Poster_19June2023
Presented at the World Congress of Dermatology, July 3-8, 2023

WCD 2023 Patient Reported Outcomes_19June2023
Presented at the World Congress of Dermatology, July 3-8, 2023

CBP-201 Efficacy by IGA severity_RAD abstract_27March2023
Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, April 30, 2023 Potentially Greater Efficacy with CBP-201 for Adults with Severe versus Moderate Atopic Dermatitis at Baseline: Subgroup Analyses from the WW001 Phase 2 Randomized Trial

2023 RAD Poster – CBP-201 Severity – 18Apr2023
Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, April 30, 2023 Potentially Greater Efficacy with CBP-201 for Adults with Severe versus Moderate Atopic Dermatitis at Baseline: Subgroup Analyses from the WW001 Phase 2 Randomized Trial

CBP-201 CN002 Pivotal_AAD 2023
Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023 CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)

AAD2023 Late Breaker 11Mar2023
Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023 CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)

CBP-201 BodyRegion_AAD 2023 Abstract
Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023 Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

EASI body region_AAD 2023 Presentation_17Mar2023
Presented at the American Academy of Dermatology Annual Meeting, March 17-21, 2023 Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)

CBP-201 investigator rated over time EADV 2022 Abstract
Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

Investigator Rated EADV 2022 Poster
Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

CBP-201 PRO over time EADV 2022 Abstract
Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

CBP-201 PRO over time EADV 2022 Abstract
Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

PRO-EADV 2022 Poster
Presented at the 31st European Academy of Dermatology and Venereology Congress (EADV), September 7-10, 2022

CBP-201, a novel and differentiated IL-4Rα targeting antibody being evaluated in Th2 inflammatory diseases
SID Annual Meeting, May 18-21, 2022

Disease Control and Quality of Life: Efficacy Outcomes from the Phase 2b Trial of CBP-201 in Patients with Atopic Dermatitis (CBP-201-WW001)
Revolutionizing Atopic Dermatitis Meeting, April 9-11, 2022

Disease Control and Quality of Life: Efficacy Outcomes from the Phase 2b Trial of CBP-201 in Patients with Atopic Dermatitis (CBP-201-WW001)
Revolutionizing Atopic Dermatitis Meeting, April 9-11, 2022

Efficacy and Safety of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD): A Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)
Presented at the Maui Derm Conference, January 24, 2022

The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD)
Presented at the Maui Derm Conference, January 24, 2022

Efficacy and Safety of CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (AD): A Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)
Presented at the Maui Derm Conference, January 24, 2022

The Effect of Baseline Disease Characteristics on Efficacy Outcomes: Results from a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)
Presented at the Maui Derm Conference, January 24, 2022

A randomized, double-blind, placebo-controlled, multiple ascending dose study of the safety, pharmacokinetics and preliminary efficacy of CBP-201 in adult patients with moderate to severe atopic dermatitis (CPB-201AU002)
Presented at the the 29th European Academy of Dermatology and Venereology Congress (EADV), October 29, 2020